CARA News and Press, Cara Therapeutics Inc. From 05/11/20

STAMFORD, Conn., May 11, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today ann...

STAMFORD, Conn., May 07, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, toda...

STAMFORD, Conn., May 04, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced tha...

You can't lump all clinical-stage biotechs together. Take  Cara Therapeutics (NASDAQ: CARA) and  Sangamo Therapeutics (NASDAQ: SGMO) , for example. The two biotechs are about as different as night and day. One thing that both Cara and Sangamo have in common, though, are promising ...

As we fast approach May, it seems as though a lot of focus continues to be paid to marijuana stocks . In the past two months, we have witnessed a large amount of bearish sentiment in the cannabis market simply due to the overwhelming issues with coronavirus. The pandemic has caused a lot of iss...

Shares of clinical-stage biotech Cara Therapeutics (NASDAQ: CARA) rose 4% Tuesday after the company reported successful results from a phase 3 trial of its lead drug Korsuva for pruritis, or severe itching, in hemodialysis patients. Based on the results, Cara and its partner, Fresenius...

Energous (NASDAQ: WATT ) +143%  on FCC certification . More news on: Energous Corporation, Vaxart, Inc., My Size, Inc., Stocks on the move, , Read more ...

Cara Therapeutics (NASDAQ: CARA ) and licensee Vifor Fresenius Medical Care Renal Pharma announce positive results from a Phase 3 clinical trial, KALM-2 , evaluating Korsuva (CR845/difelikefalin) Injection in hemodialysis patients with moderate-to-severe chronic kidney disease-associated ...

Statistically significant improvement in primary endpoint of proportion of patients with three point or greater reduction in mean Worst Itching Intensity NRS score vs. placebo (p=0.02) - Statistically significant improvement in key secondary endpoint of proportion of patients with...

Statistically significant improvement in primary endpoint of proportion of patients with three point or greater reduction in mean worst itching intensity NRS score vs. placebo (p=0.02) Statistically significant improvement in key secondary endpoint of proportion of patients with fo...